282 related articles for article (PubMed ID: 15266024)
1. Unexpected mexiletine responses of a mutant cardiac Na+ channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access.
Sasaki K; Makita N; Sunami A; Sakurada H; Shirai N; Yokoi H; Kimura A; Tohse N; Hiraoka M; Kitabatake A
Mol Pharmacol; 2004 Aug; 66(2):330-6. PubMed ID: 15266024
[TBL] [Abstract][Full Text] [Related]
2. A multifunctional aromatic residue in the external pore vestibule of Na+ channels contributes to the local anesthetic receptor.
Tsang SY; Tsushima RG; Tomaselli GF; Li RA; Backx PH
Mol Pharmacol; 2005 Feb; 67(2):424-34. PubMed ID: 15659774
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel.
Qu Y; Rogers J; Tanada T; Scheuer T; Catterall WA
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11839-43. PubMed ID: 8524860
[TBL] [Abstract][Full Text] [Related]
4. Effects of temperature and mexiletine on the F1473S Na+ channel mutation causing paramyotonia congenita.
Fleischhauer R; Mitrovic N; Deymeer F; Lehmann-Horn F; Lerche H
Pflugers Arch; 1998 Oct; 436(5):757-65. PubMed ID: 9716710
[TBL] [Abstract][Full Text] [Related]
5. Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation.
Aoike F; Takahashi MP; Sakoda S
Eur J Pharmacol; 2006 Feb; 532(1-2):24-31. PubMed ID: 16473348
[TBL] [Abstract][Full Text] [Related]
6. Sodium channel selectivity filter regulates antiarrhythmic drug binding.
Sunami A; Dudley SC; Fozzard HA
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14126-31. PubMed ID: 9391164
[TBL] [Abstract][Full Text] [Related]
7. [New aspects of the molecular effect of anti-arrhythmia agents].
Honerjäger P
Herz; 1990 Apr; 15(2):70-8. PubMed ID: 2160907
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Gating Properties and Use-Dependent Block of Nav1.5 and Nav1.7 Channels by Anti-Arrhythmics Mexiletine and Lidocaine.
Wang Y; Mi J; Lu K; Lu Y; Wang K
PLoS One; 2015; 10(6):e0128653. PubMed ID: 26068619
[TBL] [Abstract][Full Text] [Related]
9. Structural and gating changes of the sodium channel induced by mutation of a residue in the upper third of IVS6, creating an external access path for local anesthetics.
Sunami A; Glaaser IW; Fozzard HA
Mol Pharmacol; 2001 Apr; 59(4):684-91. PubMed ID: 11259611
[TBL] [Abstract][Full Text] [Related]
10. Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.
Wang GK; Russell C; Wang SY
J Physiol; 2004 Feb; 554(Pt 3):621-33. PubMed ID: 14608007
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels.
De Luca A; Natuzzi F; Desaphy JF; Loni G; Lentini G; Franchini C; Tortorella V; Camerino DC
Mol Pharmacol; 2000 Feb; 57(2):268-77. PubMed ID: 10648636
[TBL] [Abstract][Full Text] [Related]
12. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle.
Duff HJ; Offord J; West J; Catterall WA
Mol Pharmacol; 1992 Oct; 42(4):570-4. PubMed ID: 1331749
[TBL] [Abstract][Full Text] [Related]
13. A critical residue for isoform difference in tetrodotoxin affinity is a molecular determinant of the external access path for local anesthetics in the cardiac sodium channel.
Sunami A; Glaaser IW; Fozzard HA
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2326-31. PubMed ID: 10681444
[TBL] [Abstract][Full Text] [Related]
14. [The filter region of the myocardial Na channel, together with ion selectivity, controls pharmacodynamics of anti-arrhythmia agents--an analysis using the channel altered by idiopathic ventricular fibrillation].
Sasaki K
Hokkaido Igaku Zasshi; 2004 Nov; 79(6):747-54. PubMed ID: 15675305
[No Abstract] [Full Text] [Related]
15. Outward stabilization of the S4 segments in domains III and IV enhances lidocaine block of sodium channels.
Sheets MF; Hanck DA
J Physiol; 2007 Jul; 582(Pt 1):317-34. PubMed ID: 17510181
[TBL] [Abstract][Full Text] [Related]
16. Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.
Choi JS; Zhang L; Dib-Hajj SD; Han C; Tyrrell L; Lin Z; Wang X; Yang Y; Waxman SG
Exp Neurol; 2009 Apr; 216(2):383-9. PubMed ID: 19162012
[TBL] [Abstract][Full Text] [Related]
17. Lidocaine: a foot in the door of the inner vestibule prevents ultra-slow inactivation of a voltage-gated sodium channel.
Sandtner W; Szendroedi J; Zarrabi T; Zebedin E; Hilber K; Glaaser I; Fozzard HA; Dudley SC; Todt H
Mol Pharmacol; 2004 Sep; 66(3):648-57. PubMed ID: 15322257
[TBL] [Abstract][Full Text] [Related]
18. Differential interaction of R-mexiletine with the local anesthetic receptor site on brain and heart sodium channel alpha-subunits.
Weiser T; Qu Y; Catterall WA; Scheuer T
Mol Pharmacol; 1999 Dec; 56(6):1238-44. PubMed ID: 10570051
[TBL] [Abstract][Full Text] [Related]
19. Novel Brugada syndrome-causing mutation in ion-conducting pore of cardiac Na+ channel does not affect ion selectivity properties.
Amin AS; Verkerk AO; Bhuiyan ZA; Wilde AA; Tan HL
Acta Physiol Scand; 2005 Dec; 185(4):291-301. PubMed ID: 16266370
[TBL] [Abstract][Full Text] [Related]
20. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.
Nagatomo T; January CT; Makielski JC
Mol Pharmacol; 2000 Jan; 57(1):101-7. PubMed ID: 10617684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
